The Many Ways to Deal with STING

Int J Mol Sci. 2023 May 20;24(10):9032. doi: 10.3390/ijms24109032.

Abstract

The stimulator of interferon genes (STING) is an adaptor protein involved in the activation of IFN-β and many other genes associated with the immune response activation in vertebrates. STING induction has gained attention from different angles such as the potential to trigger an early immune response against different signs of infection and cell damage, or to be used as an adjuvant in cancer immune treatments. Pharmacological control of aberrant STING activation can be used to mitigate the pathology of some autoimmune diseases. The STING structure has a well-defined ligand binding site that can harbor natural ligands such as specific purine cyclic di-nucleotides (CDN). In addition to a canonical stimulation by CDNs, other non-canonical stimuli have also been described, whose exact mechanism has not been well defined. Understanding the molecular insights underlying the activation of STING is important to realize the different angles that need to be considered when designing new STING-binding molecules as therapeutic drugs since STING acts as a versatile platform for immune modulators. This review analyzes the different determinants of STING regulation from the structural, molecular, and cell biology points of view.

Keywords: IFN; STING; antiviral response.

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic*
  • Animals
  • Binding Sites
  • Nucleotides, Cyclic*

Substances

  • Nucleotides, Cyclic
  • Adjuvants, Immunologic

Grants and funding

This work was supported by Ministerio de Ciencia e Innovación PID2019-105761RB-I00/AEI/10.13039/501100011033. J.A-H. was supported by the PFIS fellowship co-funded by the FEDER/FSE and the ISCIII.